Identification of key genes and pathways in scleral extracellular matrix remodeling in glaucoma: Potential therapeutic agents discovered using bioinformatics analysis

Identification of key genes and pathways in scleral extracellular matrix remodeling in glaucoma: Potential therapeutic agents discovered using bioinformatics analysis

April 19, 2021 Off By Ava Banks

Glaucoma is a number one trigger of irreversible blindness. Remodeling of the scleral extracellular matrix (ECM) performs an vital position in the event of glaucoma. The goal of this research was to determine the key genes and pathways for the ECM remodeling of sclera in glaucoma by bioinformatics analysis and to discover potential therapeutic agents for glaucoma administration. Genes related to glaucoma, sclera and ECM remodeling have been detected using the textual content mining software pubmed2ensembl, and assigned Gene Ontology (GO) organic course of phrases and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways using the GeneCodis program.

A protein-protein interplay (PPI) community was constructed by STRING and visualized in Cytoscape, module analysis was carried out using the Molecular Complex Detection (MCODE) plugin, and GO and KEGG analyses of the gene modules have been carried out using the Database of Annotation, Visualization and Integrated Discovery (DAVID) platform. The genes that clustered in the numerous module have been chosen as core genes, and features and pathways of the core genes have been visualized using ClueGO and CluePedia. Lastly, the drug-gene interplay database was used to discover drug-gene interactions of the core genes to seek out drug candidates for glaucoma.

We recognized 125 genes widespread to “Glaucoma”, “Sclera”, and “ECM remodeling” by textual content mining. Gene useful enrichment analysis yielded 30 enriched GO phrases and 20 related KEGG pathways. A PPI community that included 60 nodes with 249 edges was constructed, and three gene modules have been obtained using the MCODE. We chosen 13 genes that clustered in module 1 as core candidate genes that have been related primarily with ECM degradation and cell proliferation and division.

The HIF-1 signaling pathway, FOXO signaling pathway, PI3K-Akt signaling pathway and TGFB signaling pathway have been discovered to be enriched. We discovered that 11 of the 13 chosen genes might be focused by 26 present medicine. The outcomes confirmed that VEGFATGFB1TGFB2TGFB3IGF2IGF1EGFFN1KNG1TIMP1, SERPINE1THBS1, and VWF have been potential key genes concerned to scleral ECM remodeling. Furthermore, 26 medicine have been recognized as potential therapeutic agents for glaucoma remedy and administration.

STATegra: Multi-Omics Data Integration – A Conceptual Scheme With a Bioinformatics Pipeline

Technologies for profiling samples using completely different omics platforms have been on the forefront for the reason that human genome venture. Large-scale multi-omics information maintain the promise of deciphering completely different regulatory layers. Yet, whereas there’s a myriad of bioinformatics instruments, every multi-omics analysis seems to begin from scratch with an arbitrary resolution over which instruments to make use of and the way to mix them. Therefore, it’s an unmet must conceptualize the way to combine such information and implement and validate pipelines in completely different circumstances.

We have designed a conceptual framework (STATegra), aiming it to be as generic as potential for multi-omics analysis, combining accessible multi-omic anlaysis instruments (machine studying element analysis, non-parametric information mixture, and a multi-omics exploratory analysis) in a step-wise method. While in a number of research, we’ve got beforehand mixed these integrative instruments, right here, we offer a scientific description of the STATegra framework and its validation using two The Cancer Genome Atlas (TCGA) case research. For each, the Glioblastoma and the Skin Cutaneous Melanoma (SKCM) circumstances, we reveal an enhanced capability of the framework (and past the person instruments) to determine options and pathways in comparison with single-omics analysis.

Such an integrative multi-omics analysis framework for figuring out options and elements facilitates the invention of new biology. Finally, we offer a number of choices for making use of the STATegra framework when parametric assumptions are fulfilled and for the case when not all of the samples are profiled for all omics. The STATegra framework is constructed using a number of instruments, that are being built-in step-by-step as OpenSource in the STATegRa Bioconductor package deal.

Identification of key genes and pathways in scleral extracellular matrix remodeling in glaucoma: Potential therapeutic agents discovered using bioinformatics analysis

Identification of Pivotal MicroRNAs and Target Genes Associated with Persistent Atrial Fibrillation Based on Bioinformatics Analysis

Atrial fibrillation (AF) is one of the most typical supraventricular arrhythmias worldwide. However, the particular molecular mechanism underlying AF stays unclear. Our research is geared toward figuring out pivotal microRNAs (miRNAs) and concentrating on genes related to persistent AF (pAF) using bioinformatics analysis. Three gene expression array datasets and an miRNA expression array dataset (GSE68475) related to pAF have been downloaded. Differentially expressed genes (DEGs) have been recognized using the LIMMA package deal, and differentially expressed miRNAs (DEMs) have been screened from GSE68475.

Target genes for DEMs have been predicted using the miRTarBase database, and intersections between these goal genes and DEGs have been chosen for additional analysis, together with the technology of protein-protein interplay (PPI) community, miRNA-transcription factor-target regulatory community, and drug-gene community. A complete of 264 DEGs and 40 DEMs have been recognized between the pAF and management teams. Functional and pathway enrichment analyses of up- and downregulated DEGs have been carried out. The widespread genes (CGs) have been primarily enriched in the phosphoinositide 3-kinase- (PI3K-) protein kinase B (Akt) signaling pathway, unfavourable regulation of cell division, and response to hypoxia.

Bead Sample Pack - Microcentrifuge Set

BSP-MC2 1pack
EUR 278.4
Description: Bead sample pack for Bullet Blender 1.5mL tube models. Includes 10mL of: ZROB015, ZROB05, ZROB10, ZROB20, SSB02, SSB14B, SSB32 and SSUFO35.

All Sample Diluents Sample Pack

KF17355 3X100 ml
EUR 326.4

PTcon SAMPLE PACK

C2125 5EA
EUR 32.34

GELLING AGENT SAMPLE PACK

G3500 1EA
EUR 17.71

Red Blood Cell Sample Pack

88R-1050 6 x 2 ml
EUR 483.6
Description: Horse, Mouse, Rabbit, Sheep, Bovine and Chicken glutaraldehyde stabilized blood cell samples

3 Blocking Buffer Sample Pack

KF17340 3 x 100 ml
EUR 246

All Assay Diluents Sample Pack

KF17351 4X100 ml
EUR 326.4

TMB Peroxidase Substrate SAMPLE PACK

42R-TB101 3 x 100 ml
EUR 393
Description: 100mL of 3 different TMB Peroxidase Substrates ready to use in immunoassays: Ultra sensitivite, Highly Sensitive, and Slow Acting.

GC/HPLC Demo Sample Pack - EACH

TNDPSSSV EACH
EUR 5.4

GC Headspace Demo Sample Pack - EACH

TNDPSSHS EACH
EUR 5.4

gPURE TISSUE SAMPLE KIT

IB47433 3ML
EUR 17.89

gPURE TISSUE SAMPLE KIT

IB47434 100ML
EUR 244.26

gPURE TISSUE SAMPLE KIT

IB47435 1L
EUR 1446.1

4% Magnetic T1 Agarose Bead

4MGT1-100 100 ml
EUR 803.25

4% Magnetic T1 Agarose Bead

4MGT1-25 25 ml
EUR 226.28

Sample Diluent Optimization Pack: 100mL SD1, SD2, SD3, PFSD

959 pack
EUR 187

Trueprep® AUTO MTB Sample Pre-treatment Pack

60204AS05 5T
EUR 5

Trueprep® AUTO MTB Sample Pre-treatment Pack

60204AS20 20T
EUR 20

Trueprep® AUTO MTB Sample Pre-treatment Pack

60205AS50 50T
EUR 50

4% Magnetic Large Agarose Bead

4MGT3-100 100 ml
EUR 803.25

4% Magnetic Large Agarose Bead

4MGT3-25 25 ml
EUR 226.28

Soft tissue tumor tissue array

BC24011b each
EUR 270
Description: Soft tissue tumor tissue array, including TNM and clinical stage, 63 cases/63 cores, replacing BC24011a

Soft tissue tumor tissue array

SF961 each
EUR 222
Description: Soft tissue tumor tissue array, including TNM and clinical stage, 48 cases/96 cores

Soft Tissue Tissue Slide (Benign)

12-303-10um 10 um
EUR 241.8

Soft Tissue Tissue Slide (Benign)

12-303-4um 4 um
EUR 216.6

Soft Tissue Tissue Slide (Abnormal)

12-305-10um 10 um
EUR 241.8

Soft Tissue Tissue Slide (Abnormal)

12-305-4um 4 um
EUR 216.6

Trueprep® AUTO Universal Sample Pre-treatment Pack

60205AB05 5T
EUR 5

Trueprep® AUTO Universal Sample Pre-treatment Pack

60205AB20 20T
EUR 20

Trueprep® AUTO Universal Sample Pre-treatment Pack

60205AB50 50T
EUR 50

Soft tissue cancer test tissue array

T241 each
EUR 48
Description: Soft tissue cancer test tissue array, with normal soft tissue control tissue, including TNM, clinical stage and pathology grade, 6 cases/24 cores

Soft tissue sarcoma test tissue array

T243a each
EUR 66
Description: Soft tissue sarcoma test tissue array,with normal soft tissue as control,TNM/Stage ( AJCC 8th edition), 6 cases/24 cores(corse size 1.5mm)

Soft tissue sarcoma test tissue array

T243 each
EUR 66
Description: Soft tissue sarcoma test tissue array, with normal soft tissue as control, including TNM and clinical stage, 2 serial sections, 6 cases/24 cores (core size 1.5mm)

Soft tissue malignant tumor tissue array

T244 each
EUR 48
Description: Soft tissue malignant tumor tissue array, including TNM and clinical stage, 6 cases/24 cores

Soft Tissue Tissue Slide (Adipose-Normal)

12-311-10um 10 um
EUR 241.8

Soft Tissue Tissue Slide (Adipose-Normal)

12-311-4um 4 um
EUR 216.6

Soft Tissue Tissue Slide (Adipose-Benign)

12-313-10um 10 um
EUR 241.8

Soft Tissue Tissue Slide (Adipose-Benign)

12-313-4um 4 um
EUR 216.6

Soft Tissue Tissue Slide (Adipose-Lipoma)

12-314-10um 10 um
EUR 241.8

Soft Tissue Tissue Slide (Adipose-Lipoma)

12-314-4um 4 um
EUR 216.6

Soft Tissue Tissue Slide (Adipose-Abnormal)

12-317-10um 10 um
EUR 241.8

Soft Tissue Tissue Slide (Adipose-Abnormal)

12-317-4um 4 um
EUR 216.6

Soft tissue sarcoma as control

SO809c each
EUR 270
Description: Soft tissue sarcoma as control, including TNM, clinical stage and pathology grade, 80 cases/80 cores (core size 1.5mm), replacing SO809b

Soft Tissue Tissue Slide (Adipose-Liposarcoma)

12-316-4um 4 um
EUR 216.6

Soft Tissue Tissue Slide (Adipose-Undiagnosed)

12-310-10um 10 um
EUR 241.8

Soft Tissue Tissue Slide (Adipose-Undiagnosed)

12-310-4um 4 um
EUR 216.6

Soft Tissue Tissue Slide (Adipose-Liposarcoma)

12-316-10um 10 um
EUR 241.8

Soft tissue tumor with normal tissue array

SO801a each
EUR 306
Description: Soft tissue tumor with normal tissue array, including TNM and clinical stage, 80 cases/80 cores, replaced by SO801b

Tumors of soft tissue, 102 cases (1.5mm)

SFT1021 1
EUR 300
Description: Soft tissue tumor tissue array, 102 cases of benign and malignant tumors of various soft tissues.

Soft tissue tumor array with autopsy tissue

T242b each
EUR 66
Description: Soft tissue tumor array with autopsy tissue, including TNM, clinical stage, 12 cases/ 24 cores, replacing T242a

Soft tissue homogenizing CK14 - PK50

HOM1044 PK50
EUR 268.65

Soft Tissue Tissue Slide (Skeletal Muscle-Normal)

12-341-10um 10 um
EUR 241.8

Soft Tissue Tissue Slide (Skeletal Muscle-Normal)

12-341-4um 4 um
EUR 216.6

Soft Tissue Tissue Slide (Skeletal Muscle-Benign)

12-343-10um 10 um
EUR 241.8

Soft Tissue Tissue Slide (Skeletal Muscle-Benign)

12-343-4um 4 um
EUR 216.6

Soft Tissue Tissue Slide (Skeletal Muscle-malignant)

12-345-10um 10 um
EUR 241.8

Soft Tissue Tissue Slide (Skeletal Muscle-malignant)

12-345-4um 4 um
EUR 216.6

Tumors of soft tissue, 75 cases (1.1mm)

SFT1501 1
EUR 300
Description: Soft tissue tumor tissue array, 150 cores, 75 cases of benign and malignant tumors of various soft tissues in duplicates.

Protein A Tell-Tale Gold® Ribbon Sample Pack, 3 x (1 cm x 30 cm)

TTGA-SP3-B090 3 x (1 cm x 30 cm)
EUR 208.7

Protein G Tell-Tale Gold® Ribbon Sample Pack, 3 x (1 cm x 30 cm)

TTGG-SP3-B090 3 x (1 cm x 30 cm)
EUR 208.7

Soft tissue tumor with adjacent normal tissue array

SO241 each
EUR 66
Description: Soft tissue tumor with adjacent normal tissue array, including TNM and clinical stage, 12 cases/24 cores

Soft tissue homogenizing CK14-0.5mL - PK50

HOM1046 PK50
EUR 268.65

Soft tissue homogenizing CK14-WP - EACH

HOM1104 EACH
EUR 365.85

Soft tissue homogenizing CK14-7mL - PK50

HOM1088 PK50
EUR 360.45

Protein A/G Tell-Tale Gold® Ribbon Sample Pack, 3 x (1 cm x 30 cm)

TTGAG-SP3-B090 3 x (1 cm x 30 cm)
EUR 208.7

Soft tissue tumor tissue array with normal tissue as control

SO481 each
EUR 198
Description: Soft tissue tumor tissue array with normal tissue as control, including TNM and clinical stage, 48 cases/48 cores

Soft tissue fibrosarcoma tissue array (2013 WHO classification)

SO961 each
EUR 306
Description: Soft tissue fibrosarcoma tissue array (2013 WHO classification), including TNM and clinical stage (AJCC 7th edition), 96 cases/96 cores

Multiple sarcoma of soft tissue array with normal tissue

SO208a each
EUR 546
Description: Multiple sarcoma of soft tissue array with normal tissue, including pathology grade, TNM and clinical stage, 64 cases/192 cores, replacing SO208

Multi-normal human tissues, FDA, 102 samples, 35 organs-sites from three individuals (1.5mm)HumanMulti-systemMulti-organsNormal

MNO1022 1.5mm
EUR 310

Bolle PACMPCT Tissues - EACH

SAF1922 EACH
EUR 11.88

Tumors of soft tissue, 48 cases (1.5mm), set 1

SFT961 1
EUR 300
Description: Soft tissue tumor tissue array, set 1, non-overlapping with SFT962, 96 cores, 48 cases of benign and malignant tumors of various soft tissues in duplicates.

Tumors of soft tissue, 48 cases (1.5mm), set 2

SFT962 1
EUR 300
Description: Soft tissue tumor tissue array, set 2, non-overlapping with SFT961, 96 cores, 48 cases of benign and malignant tumors of various soft tissues in duplicates.

Human Soft Tissue Slide (Benign) (5 slides/pk)

HTS-12303 1 pk
EUR 343.2

Common diseases of soft tissue, 24 cases (2.5mm)

SFD241 1
EUR 228
Description: Soft tissue disease tissue array, 24 cases of normal, reactive and tumor conditions of various soft tissues

Common diseases of soft tissue, 24 cases (2mm)

SFD481 1
EUR 265.2
Description: Soft tissue disease tissue array, 24 cases of reactive and tumor conditions of various soft tissues in duplicates.

Protein Safe Soft tissue homogenizing CK14 - PK50

HOM1076 PK50
EUR 375.3

Human Soft Tissue Slide (Abnormal) (5 slides/pk)

HTS-12305 1 pk
EUR 343.2

MDR Sampler Pack antibody

STJ16100969 1 pack
EUR 799.2

Magnetic COOH Sampler Pack

BLI21940-1 5ml
EUR 395

Human Soft Tissue Slide (Adipose Normal) (5 slides/pk)

HTS-12311 1 pk
EUR 343.2

Human Soft Tissue Slide (Adipose Benign) (5 slides/pk)

HTS-12313 1 pk
EUR 343.2

Human Soft Tissue Slide (Adipose Lipoma) (5 slides/pk)

HTS-12314 1 pk
EUR 343.2

Human Soft Tissue Slide (Adipose Abnormal) (5 slides/pk)

HTS-12317 1 pk
EUR 343.2

Precellys 2mL Lysing Kits - Soft tissue Starter box - PK40

HOM1060 PK40
EUR 268.65

Magnetic bead Tissue Genomic DNA Kit

PDM02-0100 100 rcs
EUR 265

Human Soft Tissue Slide (Adipose Undiagnosed) (5 slides/pk)

HTS-12310 1 pk
EUR 343.2

Human Soft Tissue Slide (Adipose Liposarcoma) (5 slides/pk)

HTS-12316 1 pk
EUR 343.2

Innovative Grade US Origin Porcine Foot Sole/Soft Tissue

IGPCFSTF each
EUR 133
Description: Innovative Grade US Origin Porcine Foot Sole/Soft Tissue

Innovative Grade US Origin Porcine Foot Sole/Soft Tissue

IGPCFSTP each
EUR 210
Description: Innovative Grade US Origin Porcine Foot Sole/Soft Tissue

Innovative Grade US Origin Porcine Foot Sole/Soft Tissue

IGPCFSTS each
EUR 210
Description: Innovative Grade US Origin Porcine Foot Sole/Soft Tissue

Innovative Grade US Origin Porcine Foot Sole/Soft Tissue

IGPCFSTZ each
EUR 133
Description: Innovative Grade US Origin Porcine Foot Sole/Soft Tissue

Magnetic Streptavidin Sampler Pack

BLI21950-1 1ml
EUR 342

Europium Chelate COOH Sampler Pack

BLI21960-1 1ml
EUR 520

Human Soft Tissue Slide (Skeletal Muscle Normal) (5 slides/pk)

HTS-12341 1 pk
EUR 343.2

Human Soft Tissue Slide (Skeletal Muscle Benign) (5 slides/pk)

HTS-12343 1 pk
EUR 343.2

BioMasher I, 1.5ml Microtube with O-ring, PE filter, soft samples

25525-120 1pack
EUR 461

BioMasher I, 1.5ml Microtube with O-ring, PE filter, soft samples

25525-30 1pack
EUR 131

BioMasher I, 2.0ml Microtube with O-ring, PE filter, soft samples

25526-120 1pack
EUR 461

BioMasher I, 2.0ml Microtube with O-ring, PE filter, soft samples

25526-30 1pack
EUR 135

Human Soft Tissue Slide (Skeletal Muscle Malignant) (5 slides/pk)

HTS-12345 1 pk
EUR 343.2

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964), 0.2mg/mL

BNUB1964-100 100uL
EUR 225
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964), 0.2mg/mL

BNUB1964-500 500uL
EUR 485
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker)(NGFR/1964), 1mg/mL

BNUM1964-50 1uL
EUR 396
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1997R), 0.2mg/mL

BNUB1997-100 100uL
EUR 225
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1997R), 0.2mg/mL

BNUB1997-500 500uL
EUR 485
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/2550R), 0.2mg/mL

BNUB2550-100 100uL
EUR 225
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/2550R), 0.2mg/mL

BNUB2550-500 500uL
EUR 485
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker)(rNGFR/1965), 0.2mg/mL

BNUB2551-100 1uL
EUR 225
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker)(rNGFR/1965), 0.2mg/mL

BNUB2551-500 1uL
EUR 485
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker)(NGFR/1997R), 1mg/mL

BNUM1997-50 1uL
EUR 396
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/2550R), 1mg/mL

BNUM2550-50 1uL
EUR 396
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker)(rNGFR/1965), 1mg/mL

BNUM2551-50 1uL
EUR 396
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964) Antibody

BNUB1964-50 50uL
EUR 486
Description: Primary antibody against NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964), 1mg/mL

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964) Antibody

BNC701964-100 100uL
EUR 279.6
Description: Primary antibody against NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964), CF770 conjugate, Concentration: 0.1mg/mL

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964) Antibody

BNC701964-500 500uL
EUR 654
Description: Primary antibody against NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964), CF770 conjugate, Concentration: 0.1mg/mL

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964) Antibody

BNC801964-100 100uL
EUR 279.6
Description: Primary antibody against NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964), CF680 conjugate, Concentration: 0.1mg/mL

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964) Antibody

BNC801964-500 500uL
EUR 654
Description: Primary antibody against NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964), CF680 conjugate, Concentration: 0.1mg/mL

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964) Antibody

BNC811964-100 100uL
EUR 279.6
Description: Primary antibody against NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964), CF680R conjugate, Concentration: 0.1mg/mL

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964) Antibody

BNC811964-500 500uL
EUR 654
Description: Primary antibody against NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964), CF680R conjugate, Concentration: 0.1mg/mL

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964) Antibody

BNC551964-100 100uL
EUR 279.6
Description: Primary antibody against NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964), CF555 conjugate, Concentration: 0.1mg/mL

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964) Antibody

BNC551964-500 500uL
EUR 654
Description: Primary antibody against NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964), CF555 conjugate, Concentration: 0.1mg/mL

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964) Antibody

BNC611964-100 100uL
EUR 279.6
Description: Primary antibody against NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964), CF660R conjugate, Concentration: 0.1mg/mL

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964) Antibody

BNC611964-500 500uL
EUR 654
Description: Primary antibody against NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964), CF660R conjugate, Concentration: 0.1mg/mL

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964) Antibody

BNC431964-100 100uL
EUR 279.6
Description: Primary antibody against NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964), CF543 conjugate, Concentration: 0.1mg/mL

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964) Antibody

BNC431964-500 500uL
EUR 654
Description: Primary antibody against NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964), CF543 conjugate, Concentration: 0.1mg/mL

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964) Antibody

BNC051964-100 100uL
EUR 279.6
Description: Primary antibody against NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964), CF405M conjugate, Concentration: 0.1mg/mL

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964) Antibody

BNC051964-500 500uL
EUR 654
Description: Primary antibody against NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964), CF405M conjugate, Concentration: 0.1mg/mL

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964) Antibody

BNCA1964-250 250uL
EUR 472.8
Description: Primary antibody against NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964), APC conjugate, Concentration: 0.1mg/mL

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964) Antibody

BNCAP1964-100 100uL
EUR 279.6
Description: Primary antibody against NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964) Antibody

BNCAP1964-500 500uL
EUR 654
Description: Primary antibody against NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964) Antibody

BNCH1964-100 100uL
EUR 279.6
Description: Primary antibody against NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964) Antibody

BNCH1964-500 500uL
EUR 654
Description: Primary antibody against NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964) Antibody

BNCP1964-250 250uL
EUR 472.8
Description: Primary antibody against NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964), PerCP conjugate, Concentration: 0.1mg/mL

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964) Antibody

BNCR1964-250 250uL
EUR 472.8
Description: Primary antibody against NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1964), RPE conjugate, Concentration: 0.1mg/mL

BioMasher I with 1.5ml Microtube with O-ring, PP filter, soft samples

25529-120 1pack
EUR 461

BioMasher I with 1.5ml Microtube with O-ring, PP filter, soft samples

25529-30 1pack
EUR 140

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1997R) Antibody

BNUB1997-50 50uL
EUR 486
Description: Primary antibody against NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/1997R), 1mg/mL

NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/2550R) Antibody

BNUB2550-50 50uL
EUR 486
Description: Primary antibody against NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/2550R), 1mg/mL

The PPI community, miRNA-transcription factor-target regulatory community, and drug-gene community have been constructed using Cytoscape. The current research revealed a number of novel miRNAs and genes concerned in pAF. We speculated that miR-4298, miR-3125, miR-4306, and miR-671-5p may signify important miRNAs that act on the goal gene superoxide dismutase 2 (SOD2) in the course of the improvement of pAF and might function important biomarkers for pAF analysis and remedy. Moreover, MYC may operate in pAF pathogenesis by means of the PI3K-Akt signaling pathway.